<DOC>
	<DOCNO>NCT00101309</DOCNO>
	<brief_summary>RATIONALE : Vaccines make person 's tumor cell white blood cell may make body build effective immune response kill tumor cell . Interleukin-2 ( IL-2 ) may stimulate white blood cell kill tumor cell . Biological therapy , cellular adoptive immunotherapy , stimulate immune system stop tumor cell grow . Giving vaccine therapy IL-2 may effective treatment Ewing 's sarcoma neuroblastoma . PURPOSE : This phase I trial study side effect vaccine therapy give IL-2 treat young patient relapse refractory Ewing 's sarcoma neuroblastoma .</brief_summary>
	<brief_title>Vaccine Therapy Interleukin-2 Treating Young Patients With Relapsed Refractory Ewing 's Sarcoma Neuroblastoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety vaccination comprise autologous tumor cell fuse Epstein-Barr virus-transformed B-lymphoblastoid cell follow interleukin-2 ( IL-2 ) child relapse refractory Ewing 's sarcoma neuroblastoma . - Determine antitumor immunity examine cell phenotype function patient treat vaccine cytotoxic T lymphocytes ( CTL ) . - Determine safety CTL IL-2 patient . OUTLINE : This pilot study . Tumor cell blood cell collect patient expand vitro . Tumor cell Epstein-Barr virus-transformed B-lymphoblastoid cell ( derive blood cell ) fuse together produce vaccine . - Vaccination : Patients receive vaccine comprise autologous tumor cell fuse Epstein-Barr virus-transformed B-lymphoblastoid cell subcutaneously ( SC ) day 0 , 14 , 28 interleukin-2 ( IL-2 ) SC twice daily day 1-7 , 15-21 , 29-35 . - Cytotoxic T lymphocytes ( CTL ) : After vaccination , patient evidence antitumor immunity undergo leukapheresis collect white blood cell CTL expansion . Some patient receive CTL IV day 0 , 14 , 28 IL-2 SC twice daily day 1-7 , 15-21 , 29-35 . Patients follow weekly 2 week , every 2 week 1 month , monthly 3 month , every 2 month 1 year post-vaccination . Patients receive CTL also follow annually survival . PROJECTED ACCRUAL : A total 10 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Sarcoma , Ewing</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis Ewing 's sarcoma OR neuroblastoma Relapsed refractory disease EpsteinBarr virus positive PATIENT CHARACTERISTICS : Age 1 30 Performance status Lansky 70100 % OR ECOG 02 Life expectancy At least 8 week Hepatic Bilirubin &lt; 2.0 mg/dL AST ALT &lt; 2.5 time normal ( absence liver metastasis ) Patients without evidence obvious relationship AST/ALT disease activity eligible Hepatitis B antigen core antibody negative Hepatitis C antibody negative Renal Creatinine clearance &gt; 50 mL/min Immunologic HIV 1 2 negative HTLV 1 2 negative Other Not pregnant Negative pregnancy test Fertile patient must use effective contraception No moribund condition PRIOR CONCURRENT THERAPY : Biologic therapy At least 3 month since prior autologous stem cell transplantation Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>recurrent neuroblastoma</keyword>
	<keyword>recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
</DOC>